Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Media, Education & Engagement
Media & CommunicationAcademic & Trade Publications
Media, Education & Engagement

pharmaphorum

Data updated

United Kingdom

Pharmaceutical industry publication that includes periodic coverage and commentary on psychedelic therapies and implementation challenges.

Media & Communication Snapshot

Academic & Trade Publications

Cadence

Daily

Access

Free

Psychedelic Focus

Psychedelic-Adjacent Focus

Verification

Verified

Audience

Industry ProfessionalsResearchersInvestors

Coverage Focus

Business & IndustryResearch & SciencePolicy & Legal

Media Notes

pharmaphorum is a pharmaceutical industry trade publication, part of EVERSANA, publishing news, analysis, deep dives, podcasts and webinars for pharma and biotech professionals. Its psychedelic coverage sits within broader pharma reporting, including Compass Pathways' COMP360 phase 3 psilocybin trials, FDA guidance on psychedelic drug development and MindMed's MM120 programme. Content is free to read, with registration required for some webinars.

Verification

Verified

Last Verified

Jul 11, 2026

Primary Media Link

Source Evidence

pharmaphorum

https://pharmaphorum.com/

Psychedelic treatments on cusp of approval, but questions remain

https://pharmaphorum.com/rd/psychedelic-treatments-cusp-approval-questions-remain

Quick Facts

Type
Other
HQ
United Kingdom
Website
Visit